Cargando…
Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
Despite advanced diseases continuing to be associated with grim prognoses, the past decade has witnessed the advent of several novel treatment options for cholangiocarcinoma (CCA) patients. In fact, CCA has emerged as a heterogeneous group of malignancies harboring potentially druggable mutations in...
Autor principal: | Rizzo, Alessandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151905/ https://www.ncbi.nlm.nih.gov/pubmed/34066684 http://dx.doi.org/10.3390/medicina57050458 |
Ejemplares similares
-
Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
por: Wu, Tianyu, et al.
Publicado: (2021) -
Novel Targeted Therapies for Advanced Cholangiocarcinoma
por: Rizzo, Alessandro, et al.
Publicado: (2021) -
FGFR inhibitors in cholangiocarcinoma: what’s now and what’s
next?
por: Saborowski, Anna, et al.
Publicado: (2020) -
Targeting the FGFR signaling pathway in cholangiocarcinoma: promise
or delusion?
por: Wang, Jing, et al.
Publicado: (2020) -
Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors
por: Casadei, Chiara, et al.
Publicado: (2019)